<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>tumor targeting peptides | LifeTein Peptide Blog</title>
	<atom:link href="https://www.lifetein.com/blog/tag/tumor-targeting-peptides/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.lifetein.com/blog</link>
	<description>LifeTein: Custom Peptide Synthesis Service</description>
	<lastBuildDate>Sun, 17 Nov 2024 03:00:05 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://www.lifetein.com/blog/wp-content/uploads/2023/10/cropped-android-chrome-512x512-1-32x32.png</url>
	<title>tumor targeting peptides | LifeTein Peptide Blog</title>
	<link>https://www.lifetein.com/blog</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Pioneering Tumor Targeting and Imaging: Conjugated Synthetic Peptides</title>
		<link>https://www.lifetein.com/blog/tumor-targeting-of-conjugated-synthetic-peptides/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=tumor-targeting-of-conjugated-synthetic-peptides</link>
		
		<dc:creator><![CDATA[LifeTein Peptide]]></dc:creator>
		<pubDate>Fri, 20 Jul 2018 19:46:11 +0000</pubDate>
				<category><![CDATA[Peptide]]></category>
		<category><![CDATA[cancer peptide]]></category>
		<category><![CDATA[cancer targeting peptide]]></category>
		<category><![CDATA[ovarian cancer]]></category>
		<category><![CDATA[tumor targeting peptides]]></category>
		<guid isPermaLink="false">https://www.lifetein.com/blog/?p=489</guid>

					<description><![CDATA[<p>The folate receptor alpha (FRα) is highly expressed in ovarian cancer and not in normal tissues. An FRα binding peptide C7 (Met-His-Thr-Ala-Pro-Gly-Trp-Gly-Tyr-Arg-Leu-Ser, MHTAPGWGYRLS)  was found to bind to FRα expressing cells. This tumor-targeting peptide was proved by both phage homing &#8230; <a href="https://www.lifetein.com/blog/tumor-targeting-of-conjugated-synthetic-peptides/">Continue reading <span class="meta-nav">&#8594;</span></a></p>
The post <a href="https://www.lifetein.com/blog/tumor-targeting-of-conjugated-synthetic-peptides/">Pioneering Tumor Targeting and Imaging: Conjugated Synthetic Peptides</a> first appeared on <a href="https://www.lifetein.com/blog">LifeTein Peptide Blog</a>.]]></description>
										<content:encoded><![CDATA[<p>The folate receptor alpha (FRα) is highly expressed in ovarian cancer and not in normal tissues. An FRα binding peptide C7 (Met-His-Thr-Ala-Pro-Gly-Trp-Gly-Tyr-Arg-Leu-Ser, MHTAPGWGYRLS)  was found to bind to FRα expressing cells. This tumor-targeting peptide was proved by both phage homing experiment and fluorescence imaging.</p>
<p>Tumor Targeting of Conjugated Synthetic Peptides<br />
1. The FITC-conjugated peptide FITC-MHTAPGWGYRLS was dissolved in PBS.<br />
2. The peptide was injected intravenously into a tumor-bearing nude mouse.<br />
3. After 2 h, the tumor and other organ tissues were harvested and analyzed using a fluorescence imaging system.</p>
<p>Cell internalization of Synthesized Peptide<br />
1. Cells were seeded in 24 well plates containing coverslips and incubated for 24 hours in a medium with FBS.<br />
2. FITC conjugated peptide was incubated with the cells for 4 hours at 37 °C.<br />
3. The cells were washed once with PBS and fixed in 4% paraformaldehyde.<br />
4. Cells were washed three times with PBS and stained with DAPI for 20 min at room temperature.<br />
5. Internalized fluorescent signals were imaged with a confocal microscope.</p>
<p>This tumor-specific peptide could be a potent and selective ligand for FRα. It has a great potential for the delivery of cancer therapeutics or imaging agents to express tumors.</p>
<p>Reference: Scientific Reports, volume 8, Article number: 8426 (2018)</p>
<div id="attachment_490" style="width: 310px" class="wp-caption aligncenter"><img fetchpriority="high" decoding="async" aria-describedby="caption-attachment-490" class="size-medium wp-image-490" src="https://www.lifetein.com/blog/wp-content/uploads/2018/07/Tumor-targeting-peptides-300x269.jpg" alt="tumor targeting peptides" width="300" height="269" srcset="https://www.lifetein.com/blog/wp-content/uploads/2018/07/Tumor-targeting-peptides-300x269.jpg 300w, https://www.lifetein.com/blog/wp-content/uploads/2018/07/Tumor-targeting-peptides-334x300.jpg 334w, https://www.lifetein.com/blog/wp-content/uploads/2018/07/Tumor-targeting-peptides.jpg 382w" sizes="(max-width: 300px) 100vw, 300px" /><p id="caption-attachment-490" class="wp-caption-text">tumor targeting peptides</p></div>The post <a href="https://www.lifetein.com/blog/tumor-targeting-of-conjugated-synthetic-peptides/">Pioneering Tumor Targeting and Imaging: Conjugated Synthetic Peptides</a> first appeared on <a href="https://www.lifetein.com/blog">LifeTein Peptide Blog</a>.]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>

<!--
Performance optimized by W3 Total Cache. Learn more: https://www.boldgrid.com/w3-total-cache/?utm_source=w3tc&utm_medium=footer_comment&utm_campaign=free_plugin


Served from: www.lifetein.com @ 2026-04-14 14:26:21 by W3 Total Cache
-->